Corporate Management
AMAG Pharmaceuticals is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of atherapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company has three commercial products: Feraheme® (ferumoxytol) Injection, Feridex I.V.® and GastroMARK®
Core Technology of AMAG Pharmaceuticals, Inc.
Our core technology is based on the characteristic properties of ultra small, semi synthetic coated iron oxide particles. Our core competencies include the ability to design such particles for particular applications, to manufacture the particles in controlled sizes and to cover the particles with different coatings depending upon the application for which they will be used.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy. Additionally, the superparamagnetic characteristic of our products results in particles that become strongly magnetic when placed in a magnetic field, but lose their magnetism once the field is removed. Therefore, use of these particles may result in magnetic resonance images that increase the information available to the reviewing physicians.
Our technology and expertise enable us to synthesize, sterilize and stabilize iron oxide particles in a manner necessary for use in pharmaceutical products such as iron replacement therapeutics and magnetic resonance imaging contrast agents.
Iron - A Critical Element in the Body
Iron is critical to a number of processes in the human body and is a key component of the hemoglobin molecule where it serves a vital role in oxygen transport from the lungs to tissues. Low levels of iron in the body is known as iron deficiency and can result in anemia and inadequate oxygen delivery to different organs. Iron deficiency anemia can result when there is an inadequate amount of hemoglobin in red blood cells. Iron deficiency anemia is associated with a number of symptoms including fatigue, lethargy, poor concentration, shortness of breath, palpitations, and dizziness. Low levels of red blood cells can occur because of iron deficiency anemia, blood loss, and/or decreased production of the hormone erythropoietin. Intravenous iron replacement therapy plays a major role, along with erythropoietic stimulating agents, in treating certain types of chronic anemia in patients suffering from chronic kidney disease. Iron deficiency anemia is also common in patients with other conditions and diseases such as abnormal uterine bleeding, cancer and gastrointestinal diseases.
To learn more about iron deficiency anemia visit www.IDAnemia.com
Corporate Information